BALAJI AMINES LTD.-$
P&L
Quarterly Consolidated
vs Q2 FY25
Balaji Amines Q3FY25 Revenue at ₹ 321 Crore, Net Profit at ₹ 31 Crore
13 Feb 2025 · 13 Feb 2025, 02:32 am
Summary
Balaji Amines Limited, a leading manufacturer of Aliphatic Amines & Speciality Chemicals in India, announced its unaudited financial results for the quarter and nine months ended December 31, 2024. The company reported a consolidated Q3FY25 revenue of ₹ 321 crore, EBITDA of ₹ 54 crore, and net profit of ₹ 31 crore. The total volumes stood at 24,097 MT for Q3FY25 as against 26,348 MT in Q2FY25. The company is adding additional equipment to the existing DMC/PG plant and proposing to set up a plant for manufacture of N-(N-Butyl) Thiophosphoric Triamide (NBPT) with a capacity of 2500 TPA. The company is also investing in a wide range of products, including Hydrogen Cyanide (HCN), Sodium Cyanide (NaCN) 30% (Solution), Sodium Cyanide (NaCN) 100% (Solid), Ethylene Diamine Tetra Acetic Acid (EDTA), Ethylene Diamine Tetra Acetic Acid Disodium Salt (EDTA-2Na), Benzyl Cyanide (BnCN), Phenylacetic Acid (PAA), and Tri Ethyl Ortho Formate (TEOF) / Tri Methyl Ortho Formate (TMOF).
Key Highlights
- 1
Consolidated Q3FY25 Revenue stood at ₹ 321 Crore
- 2
EBITDA stood at ₹ 54 Crore
- 3
Net Profit stood at ₹ 31 Crore
- 4
Total volumes stood at 24,097 MT for Q3FY25
- 5
Proposing to set up a plant for manufacture of N-(N-Butyl) Thiophosphoric Triamide (NBPT) with a capacity of 2500 TPA
- 6
Investing in a wide range of products, including Hydrogen Cyanide (HCN), Sodium Cyanide (NaCN) 30% (Solution), Sodium Cyanide (NaCN) 100% (Solid), Ethylene Diamine Tetra Acetic Acid (EDTA), Ethylene Diamine Tetra Acetic Acid Disodium Salt (EDTA-2Na), Benzyl Cyanide (BnCN), Phenylacetic Acid (PAA), and Tri Ethyl Ortho Formate (TEOF) / Tri Methyl Ortho Formate (TMOF)
Management Comments
Mr. D. Ram Reddy
Managing Director
During Q3 FY25, our financial and business performance remained stable despite the challenges posed by global macroeconomic conditions. However, as volume uptake gradually increases, EBITDA and PAT margins are expected to improve in line with industry recovery. The resurgence in domestic demand, along with positive trends in international markets, is driving this momentum. Additionally, the utilization of expanded capacities will contribute to margin enhancement, as some of our products progress through the final approval stages with end-user industries. This progress is further supported by our ongoing investments in key projects, reinforcing our commitment to operational excellence. Electronic Grade DMC, Propylene Glycol Pharma Grade and Dimethyl Ether projects are progressing well, aligning with our strategic growth objectives. These initiatives are designed to strengthen our market presence, enhance product offerings, and meet the evolving needs of our customers. Looking ahead, we maintain a positive outlook for long-term opportunities, anticipating growth and increased prospects during the fiscal year 2025-26. Our focus on inherent strengths and competencies positions us as a leading force in Amines and Specialty Chemicals, guiding us through market complexities towards greater excellence.
Informational and educational content only. Not investment advice.